TrialGynecologic oncology2023

Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.

Sandro Pignata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.